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Abstract There are two TGF-~ binding subdomains in the ex- 
tracellular domain of receptor type III (proximal and distal in 
relation to the transmembrane domain). Here we present an ex- 
tension of our analysis of the proximal binding site of receptor 
type III. Due to the original deletion mutagenesis trategy, our 
proximal binding site contained 19 amino acids from the N- 
terminal part of the receptor. By deleting these, we demonstrated 
that they did not contribute to the binding ability of the proximal 
binding site. We also produced a soluble, secreted form of the 
proximal binding site and demonstrated that it was able to bind 
TGF-I~. Finally, we analyzed the role of the three asparagine 
residues (580, 591, 595) that are located in the region of the 
receptor that is necessary for expression of a functional proximal 
binding site, and found that mutation of these residues individually 
to alanine did not affect ligand binding. 
Key words'. Transforming rowth factor-fl receptor type 1ii: 
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1. Introduction 
Transforming rowth factor/3 (TGF-~) is a member of a 
superfamily of growth and differentiation factors that include 
activins, inhibins, the bone morphogenetic proteins and related 
morphogenetic peptides. TGF-~s (1-3 in mammals) are closely 
related secreted peptides which regulate xtracellular matrix 
formation, cell growth and differentiation, morphogenesis and 
immune responses [1 6]. Most cells display three types of cell 
surface receptors which can bind and be chemically cross- 
linked to TGF-fl. Those three TGF-fl receptors are termed 
receptor type I (53 kDa), type II (73 kDa) and type III (280 
kDa) and can be divided into the signaling receptors (type I and 
type II) and non-signaling receptors (type III and the related 
receptor endoglin) [1,2,7 12]. Receptor type III is thought o 
act as an enhancer of TGF-~ access to the signaling receptors 
[13,14] but not to signal in itself. 
The receptors type I and type II seem to be directly involved 
in signal transduction since the loss of expression of either the 
type I or the type II receptors results in the loss of response to 
the growth-inhibitory effect of TGF-fl in tumor cell lines 
[3,10,15- 17] or in mutagenized mink lung epithelial cells [18 
21], TGF-~ receptors type I and type I1 are related to each other 
*Corresponding author. Present a&#ess 610(I Royalmount Avenue. 
Montreal, Quebec, Canada H4P 2R2. Fax: (I)(514) 496-6213. 
Abbreviations. TGF-,& transforming growth factor-fl: GAG. glycosam- 
inoglycan. 
[22,23]. Their cytoplasmic domains contain serine/threonine ki- 
nase activity suggesting that they mediate a phosphorylation- 
dependent transduction of signal [11,23 25]. Receptor type I is 
a 53 kDa transmembrane protein which requires the presence 
of receptor type II in order to bind TGF-fl [11,20,24]. On the 
other hand, receptor type II is a 73 kDa protein that can 
independently bind TGF-fl [23] but requires the presence of 
receptor type I for signaling [11]. 
Receptor type III is coexpressed with receptor type I and 
type lI in various cell types and in most cases is the major 
TGF-fl binding molecule on the cell surface [3,10,26,27]. It 
exists as a proteoglycan with heparin and chondroitin sulfate 
chains: however, TGF-fl can bind to the core of the receptor 
in the absence of glycosaminoglycan chains [28,29]. Receptor 
type III is a transmembrane protein with a short cytoplasmic 
domain showing no apparent signaling motif [30,31,32]. The 
absence of an obvious signaling domain, together with the fact 
that various TGF-fl responsive cells lack the type III receptor 
[10,33,34] has led to the proposal that the type III receptor does 
not participate directly in TGF-fl signal transduction. How- 
ever, receptors type 1 and I1 bind TGF-fll and TGF-fl3 with 
higher affinity than TGF-fl2 [7,10,35] and this difference is 
more pronounced in cells that lack the receptor type III [33,35]. 
This led to the suggestion that receptor type III might modify 
the responsiveness of cells to various isoforms of TGF-fl. More 
recently results which demonstrated a direct association be- 
tween the type III and signaling receptors provided strong 
support for the role of the receptor type III in delivering TGF-fl 
to the signaling receptors [13,14]). It has been shown that when 
receptor type III is overexpressed in transfected cells, it in- 
creases the affinity of receptor type II for TGF-fl2 [13]. How- 
ever, when expressed in the cell media as a secreted form, the 
extracellular domain of receptor type III decreases the labeling 
of receptor type II and type I and reduces the magnitude of the 
cell's response to TGF-~ as if it was sequestrating TGF-fl [36]. 
We have previously reported the analysis of a number of 
deletion mutants of the TGF-fl receptor type III. The shortest 
binding mutant (344-575) defined a ligand binding region in the 
210 amino acids of the extracellular domain which flank the 
transmembrane domain [37]. Another group also showed the 
existence of a binding site in this region using E. coli expression 
of fragments of the receptor type III [38]. An approach similar 
to ours was used by Lopez-Casillas et al. and they demon- 
strated the existence of a TGF-// binding domain at the N- 
terminal part of the extracellular domain [36]. Two TGF-~ 
binding domains have thus been identified in receptor type III. 
The first lies at the N-terminus of the extracellular domain [36]. 
The other lies at the C-terminal end of the extracellular domain 
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in a juxtamembrane position [37,38]. These domains are re- 
ferred to here as the distal and proximal binding sites respec- 
tively with respect o their location relative to the transmem- 
brane domain. The significance of the presence of the two 
TGF-f l  binding sites in receptor type II1 is unclear at present. 
However, when expressed as secreted proteins both the distal 
[36] and the proximal [38] binding site are able to modulate 
TGF-fl  access to the cells. 
Here, we have extended our analysis of the proximal binding 
site of receptor type III. In order to confirm that the proximal 
binding site is independent from N-terminal sequences (i.e. 
from the distal binding site), we have deleted the 19 N-terminal 
amino acids from mutant A44-575. We show that this mutant 
(A26-575) binds TGF-fl, thus ruling out the possible contribu- 
tion of N-terminal sequences to the binding ability of the prox- 
imal binding site. Moreover, we have produced a secreted ver- 
sion of mutant A44-575 which is able to bind TGF-fl  indicating 
that the proximal binding site does not require the cell mem- 
brane or membrane proteins to bind TGF-fl. We have also 
performed site directed mutagenesis on mutant 344-575 to ex- 
plore the role of putative N-glycosylation sites in a segment (aa 
576-596) whose deletion negates expression of an active TGF-/3 
binding site. These results indicate that asparagine-591 is nor- 
mally glycosylated, but that this glycosylation event is not re- 
quired for the expression or binding ['unction of the proximal 
binding site. 
2. Materials and methods 
2.1. Vector construction 
A vector coding for a secreted version of 344-575 (A44-575sv) was 
produced by replacing amino acid-783 (a glycine which lies 3 aa up- 
stream the transmembrane domain) by an opal stop codon. Primer 
RTB3 2642:stop (5'-CCGA.A.TTCTCA.A.-'*6~TGGA.A.A.A.TCT - 
GTGGAGG2648-3'; numbers refer to the numbered sequence published 
by Lin et al. [23]) which bears the glycine to stop mutation was 
used along with primer Xba5.1(3) (5'-CCTCTAGA24A.A.GC - 
GGGCTGCTGTCCTTC4L3 ' located in the 5' leader) to PCR amplil} 
the coding region of 344-575. The PCR fragment was gel purified. 
phosphorylated and sub-cloned blunt-ended at the EcoRV site ot 
pCDNA3. 
A myc epitope was added to mutants A44-575 and A44-596; these are, 
respectively, the shortest binding mutant and the longest non-bind- 
ing mutant from our previous work [37]. Four primers were used 
for this cloning. Primer Xba5. l(3) is located in the 5' leader of receptor 
type lII cDNA. Primer R3L (5'-TCGA.A.TTCC-'99°GGGCGTC - 
TGTCTGTCCAC2~82-3 ') is located in the 3' non-translated sequence of 
receptor type III cDNA. Primer Myc.1 is a chimeric primer pointing 
toward the 5'-end of the cDNA and linking the sequence for amino 
acids 25 30 of receptor type It1 to the sequence for amino acids EQKLI 
(the N-terminal portion of the Myc epitope) (5'-AT- 
CAGCTTCTGTTCCTCGC~X>SGGGTGCTGGGCTCTGGA39 ~- '). 
Primer Myc.2 points toward R3L and links amino acids SEEDLL 
(the C-terminal portion of the Myc epitope) to amino acids 31 to 
36 of receptor type III (5'-CTCCGAGGA.A.GATCTGCTG~(~TG - 
TGA.A.CTGTCACCA.A.T42~-3'). Primer Myc.l was phophorylated 
and used along with Xba5.1(3) to PCR amplify the 5' portion of the 
cDNA (410 bp) with Vent DNA polymerase (New England Biolabs). 
Primer Myc.2 was used along with R3L to PCR amplify the 3' portion 
of the cDNA (2518 bp) with Vent DNA polymerase. Both fragments 
were ligated together, gel purified to isolate the expected 2928 bp band 
which was then phosphorylated and cloned into EcoRV-digested and 
dephosphorylated pCDNA3 vector. 
Asparagine to alanine mutants were produced by USE mutagenesis 
(Pharmacia) using pCDNA3-(A44-575) as the parent vector. The selec- 
tion primer was designed to mutate the unique Kpnl site of the multiple 
cloning site of pcDNA3(A44-575) to a unique Nhel site (Primer KtoN: 
5'-CCGAGCTCGCTAGCA.A.GCTTGGGTC-3'). Primer RT3-N580 
(5'-G:""~CCACTGGGAGCCCTCAGCTGC2°4~-3'), RT3-N591 (5'- 
G'"~tA.A.GGTAGCAGCTCCATCGAGC2C'a°-3 ') and RT3-N595 (5'- 
C~;AGCTCCATGGCGA.A.GGTAGC2°93-3&prim e;) were used to 
produce A44-575N580A, A44-575N591A and A44-575N595A, respec- 
tively. 
A26-575(Myc) was produced by USE mutagenesis using 
pcDNA3(A44-575) as the parent vector, KtoN as the selection 
primer and M6Myc-20 (5'-T2°5~TCCTCAGCTGCCGZ°45CAGATCTr - 
CCTCGGAGATCAGCTTCTGTTCT~GGACCGGCGGTGG381-3 ') 
as the mutagenic primer. This primer loops out the sequence corre- 
sponding to amino acids 26~43 of receptor type III and replaces it with 
the Myc epitope (EQKLISEEDL). 
The sequence of every mutant was confirmed by dideoxy nucleotide 
sequencing. 
2.2. ('ell culture and transJection procedure 
Cos-I cells were grown in Dulbeco's Modified Eagle Medium 
I DMEM) supplemented with 10% fetal calf serum. Cells were tran- 
siently transfected according to the procedure of Chen and Okayama 
[39]. Transfections were performed using 20/~g of expression vector and 
5 × 10 s cells per 6-well plate. Binding of TGF-fl to the mutant receptors 
was monitored 48 h after transfection by a ligand binding and cross- 
linking assay. 
Z3. Bh~ding assay 
The binding and cross-linking assays were performed on transfected 
cells as previously described [40] using TGF-fll (supplied by Bristol- 
Myers-Squibb Pharmaceutical Research Institute, Seattle, WA) or 
TGF-fl2 (supplied by Celtrix Laboratories Inc., Palo Alto, CA) which 
was iodinated as described in Philip and O'Connor-McCourt [41]. For 
the cross-linking assay which was performed on cell media, the follow- 
ing procedure was used. 48 h after transfection, cell media was har- 
vested, buffered with 50 mM Na2HPO4 pH7.4 and incubated with 200 
pM of [t25I]TGF-f12 (with or without 20 nM unlabeled TGF-fl2) for 
3 h at 4°C. Cross-linking was performed for 2 rain at 4°C by addition 
of 1/10 volume of 10 mM bis sulfosuccinimidyl suberate (BS3) and was 
stopped by addition of 1/5 volume of 625/IM glycine. Cross-linked 
receptors were analyzed by polyacrylamide g l electrophoresis (under 
reducing conditions) and autoradiography. 
The expression of the myc-tagged mutants was confirmed by Western 
blotting using antibody 9El0 which is directed against he myc epitope 
[421. 
3. Results and discussion 
3.1. The proximal binding site c)f receptor type l I I  binds" TGF-fl 
independently 0[ N-terminal sequences 
The TGF-fl  binding site of receptor type III has been mapped 
independently by three laboratories to two different subdo- 
mains of the extracellular domain (Fig. 1). One site has been 
mapped proximal to the transmembrane domain by Fukushima 
et al. [38] and our group [37]. This region shares distant homol- 
ogy with a subdomain of uromodulin and other proteins [43] 
(Fig. 1). Another TGF-fl  binding site was mapped to the N- 
terminus end of the extracellular domain of the receptor type 
I l l  by Lopez-Casillas et al. [36]. This region shows homology 
to endoglin, a TGF-f l  binding membrane protein that is ex- 
pressed predominately on endothelial cells [26]. Although it was 
initially difficult to reconcile the results of Fukushima et al. [38] 
and ourselves [37] with those of Lopez-Casillas et al. [36], it has 
since been confirmed in three different laboratories that the 
mutants which contain the N-terminal site as identified by 
Lopez-Casillas et al. [36] and the mutants which contain the 
C-terminal site as identified by our group [37] are all able to 
bind TGF-f l  (F. Lopez-Casillas and J. Massagu6, personal 
communication; and K. Myazono, personal communication; 
M.-C. Pepin, data not shown). 
It should be noted, however, that, owing to the deletion 
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I Endoqlin }- - - - [ - -7  
I Uromodulin I .'~,,<, 
I Distal I I Proximal I 
1 1 I I I  1 '4"°,4,~ 
A44-575 + 
A26-575 + 
&44-575sv  + 
A44-596 
Z144-575 
)/ NS80A + 
x A44-575 
N591A + 
~( A44-575 
N595A + 
Fig. 1. Schematic representation of TGF-fl receptor type III and 
various mutants (produced during this work) with a summary of 
their TGF-fl binding ability. Regions of homology with endoglin 
and uromodulin are shown by overlying boxes as well as the loca- 
tion of the proximal and distal TGF-,8 binding sites. Black box-  
signal peptide; hatched box = transmembrane domain; black 
dots = glycosaminoglycan ttachment chains: stars = putative N-gly- 
cosylation sites. 
mutagenesis strategy that we used originally [37], there are 19 
amino acids from the N-terminal part of the receptor that are 
present in mutant 344-575 (i.e. our shortest binding mutant 
which defined the proximal binding site [37]). in order to rule 
out the possibility that these amino acids from the distal bind- 
ing site might be contributing to the binding ability of mutant 
344-575, we created mutant A26-575 by deleting amino acids 
26-43 from mutant 344-575 and replacing them with a myc 
epitope. COS-I cells were transfected with the expression vec- 
tor for mutant A26-575, and also with mutant 344-575 and 
mutant A44-596 as positive and negative controls. Cells were 
affinity-labeled with iodinated TGF-fl. and the cell extracts 
were separated by electrophoresis and revealed by autoradi- 
ography. Fig. 2 shows the labeling patterns that were obtained. 
As previously reported, mutant A44-575 appears as a doublet 
centered around 55 kDa along with higher molecular weight 
species which are thought to be cross-linked multimers of mu- 
tant A44-575. Also as expected, transfection of cells with mu- 
tant A44-596 did not yield any labeling with ['~51]TGF-fl2 (even 
though mutant A44-596 is expressed: see below). Mutant A26- 
575 is clearly labeled by [~zSI]TGF-fl2 (Fig. 2) indicating that the 
N-terminal sequence (aa 26 to 43) does not make an essential 
contribution to the binding ability of mutant A44-575. i.e. the 
proximal binding site. That the proximal site binds independ- 
ently from N-terminal sequences i supported by the results oJ" 
Fukushima et al. [38] since their bacterially produced fusion 
protein which included amino acids 543-769 of receptor type 
I l l  behaved as a TGF-fl  binding protein. The labeling pattern 
of mutant 326-575 is similar to but distinct from that of mutant 
444-575. The oligomeric forms of the receptor are present as 
observed with mutant A44-575. However, whereas mutant A44- 
575 appears as a doublet, mutant A26-575 migrates as a single 
band with an apparent molecular weight approximately the 
same as that of the fastest migrating of the two A44-575 bands. 
This result may be explained by heterogeneity of glycosylation 
at the predicted N-glycosylation site, asparagine-37. If this site 
is glycosylated in only half of the molecules of mutant 344-575, 
this mutant should appear as doublet and this was observed. 
Since asparagine-37 is deleted in mutant A26-575, this source 
of heterogeneity would be lost and mutant A26-575 should 
appear as a single band co-migrating with the fastest migrating 
form of mutant A44-575, as was observed. 
3.2. The proximal binding site of receptor type III binds TGF-fl 
independently ofmembrane anchorage 
In order to confirm that the proximal site is a bona fide 
TGF-f l  binding subdomain independent from accessory struc- 
tures or proteins on the cell surface, we produced a secreted 
version of mutant A44-575 and analyzed its ability to bind in 
a cell-free nvironment. Mutant zt44-575sv (for soluble version) 
was created by inserting a stop codon at position 783, 3 amino 
acids upstream of the transmembrane domain. When media 
from transfected cells were affinity labeled, a TGF-fl  binding 
protein of the expected size was observed for cells transfected 
with mutant A44-575sv, but not with mutant A44-575 or mock- 
transfected cells (Fig. 3). These results demonstrate that the 
proximal binding site is functional when secreted from cells in 
a soluble tbrm. 
3.3. The non-binding mutant (A44-596) is expressed 
In our previous work [37], we observed that deletion mutant 
A44-596 could not be detected by affinity-labeling, suggesting 
that this mutant is unable to bind TGF-fl  or that it is not 
expressed at the cell surface. To verify the expression of mutant 
A44-575 A44-596 B26-575 
Unlabeled 
TGF-1$2 I _ + U-  + I I _  + I 
200 
l> 
D 
Free TGF-~ 
97 
68 
..... 43 
29 
Fig. 2. TGF-fl2 affinity-labeling of Cos-1 cells transiently transfected 
with expression vectors for deletion mutants of TGF-fl receptor type 
lit. Cell transfection, affinity-labeling and gel electrophoresis were 
done as described in section 2. The presence or absence of unlabeled 
competitor is shown by the + or - signs. The filled arrow headpoints 
to the monomeric form of the mutants whereas the empty arrow heads 
point toward labeled species of higher apparent molecular weight hat 
are thought o be oligomers of the receptor mutants. Molecular weight 
markers in kDa are shown on the right hand site. 
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97 
68 
43 
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Fig. 3. TGF-fl2 affinity-labeling performed on culture media of cells 
transfected with an expression vector for a secreted form of A44-575 
(A44-575sv). Cell transfection, affinity-labeling and gel electrophoresis 
were as described in section 2. The arrowhead points to the labeled 
soluble form of the proximal binding site. The molecular weight mark- 
ers are shown on the right-hand side. 
A44-596, we added a c-myc epitope on mutant A44-596. and also 
on mutant A44-575 as a control. When transfected in COS-I 
cells, both constructs yielded bands around the expected molec- 
ular weight hat could be detected using the anti-myc monoclo- 
nal antibody 9El0 [42] on Western blot (Fig. 4). Mutant A44- 
575 appears as a doublet of 41 and 44 kDa whereas its predicted 
molecular weight is 32.8 kDa. Mutant A44-596 shows up as a 
triplet of 39, 42 and 46 kDa whereas its predicted molecular 
weight is 30.5 kDa. As discussed above tbr mutant A44-575. the 
appearance of the doublet and triplet is likely due to heteroge- 
neity of glycosylation. The difference in molecular weight be- 
tween the fastest migrating band of each mutant (41 kDa 39 
kDa) is consistent with the difference xpected from their pre- 
dicted molecular weights (32.8 - 30.5). The higher apparent 
molecular weight of the affinity labeled form of mutant A44-575 
as compared to that of the Western blot (Fig. 4) is due to the 
presence of a cross-linked monomer of TGF-/5' (12.5 k Da I. 
In order to demonstrate hat the myc tagged J44-596 is not 
only expressed, but is also localized at the cell surface. ~e 
attempted cell surface labeling, immunocytochemistry andgly- 
cosylation pattern analysis, but none of these experimental 
approaches gave conclusive results. Deglycosylation experi- 
ments showed that the majority of the expressed A44-596 and 
A44-575 mutants was sensitive to endoH (data not shown). This 
demonstrates that in our transfection experiments, the majority 
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of the expressed proteins have immature glycosylation chains 
suggesting that they are retained inside the cells. However, it 
is evident hat some of mutant A44-575 reaches the cell surface 
since it can be labeled by TGF-fl. 
3.4. Analysis of potential glycosylation sites in the 576 596 
region q['mutant A44-575 
Since mutant A44-575 binds TGF-fl and mutant A44-596 does 
not, it appears that amino acids 576-596 are necessary for the 
expression of a functional proximal binding site at the cell 
surface. In order to identify important residues in these 20 
amino acids, we independently mutated to alanines three aspar- 
agines located at position 580, 591 and 595 of mutant A44-575 
(A44-575N580A, A44-575N591A, A44-575N595A). The mutant 
vectors were transiently transfected in COS-1 cells that were 
affinity-labeled using [125I]TGF-f12. It can be seen in Fig. 5 that 
the three mutants bind TGF-fl indicating that these amino acids 
are not critical for the transport, folding and binding function 
of the proximal binding site. Moreover, it can be seen that all 
the labeled species observed with mutant A44-575N591A have 
a lower apparent molecular weight han those of mutants A44- 
575N585A and A44-575N595A (which both co-migrate with 
mutant A44-575; data not shown). This strongly suggests that 
asparagine-591 is glycosylated, consistent with predictions 
made from analysis of the sequence [31,32]. The glycosylation 
of this site is not critical for TGF-fl binding, a finding consistent 
with the fact that the proximal binding site produced in bacteria 
behaves as a TGF-fl binding protein [38]. 
We conclude from our work that the domain covering amino 
acids 575 783 of TGF-fl receptor type III is a bone fida TGF-fl 
binding subdomain which is active independent of N-terminal 
sequences and anchorage to the cell membrane. Whether the 
distal and proximal binding sites of TGF-fl receptor type It1 
have different independent functions or act in concert is 
unknown. Work is currently in progress to overexpress the 
A44-575 A44-596 A44-575 A44-596 
Unlabeled 
D 
Free TGF-~ 
- -  200 
I97  
m68 
m43 
~29 
I I I i 
125I_TGF.132 9El0 
Fig. 4. Analysis of expression of the non-binding mutant A44-596. 
Cos-[ cells were transfected with the expression vector for A44- 
575(Myc) or A44-596(Myc) and affinityqabeled with [lZSI]TGF-fl. Cell 
extracts were submitted togel electrophoresis and transferred tonitro- 
cellulose. The membrane was submitted to autoradiography 
I[P'I]TGF-fl2. left panel) and revealed with a monoclonal antibody 
against the Myc epitope (9El0), right panel. Unlabeled receptors mi- 
grate faster than the labeled ones because the latter are cross-linked to
TGF-fl monomers (12.5 kDa). Arrow heads and molecular weight 
markers are as in Fig. 2. 
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A44-575 A44-575 A44-575 
Unlabeled N580A N591A N595A 
TGF-[].2 I _ 4. I Im 4 -U-  .].1 
200 
1> 
I> 
Free TGF-~ 
97 
68 
43 
29 
Fig. 5 TGF-fl2 affinity-labeling of Cos-1 cells transfected with expres- 
sion vectors lbr mutants of A44-575 carrying asparagine to alanine 
substitutions. Cell transfection, affinity-labeling and gel electrophoresis 
were as described in section 2. Arrowheads and molecular weight mark- 
ers are as in Fig. 2. 
secreted version of mutant A44-575 to study its binding charac- 
teristics in more detail. 
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